I-BET151 (GSK1210151A)

For research use only. Not for use in humans.

目录号：S2780

I-BET151 (GSK1210151A) Chemical Structure

CAS No. 1300031-49-5

I-BET151 (GSK1210151A)是一种新型，选择性的BET抑制剂，作用于BRD2，无细胞试验中BRD3和BRD4，IC50分别为0.5 μM， 0.25 μM和0.79 μM。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 2121.21	现货
5mg	RMB 1382.25	现货
10mg	RMB 2231.18	现货
50mg	RMB 7130.63	现货
100mg	RMB 10401.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的I-BET151 (GSK1210151A)发表文献33篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):922-938

PubMed: 30537514 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1045

PubMed: 33594072 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgaa986

PubMed: 33417713 ( click the link to review the publication )

Genome Biol, 2020, 21(1):269

PubMed: 33143730 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1833

PubMed: 32286255 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33000

PubMed: 32249419 ( click the link to review the publication )

Genomics Inform, 2020, 18(4):e37

PubMed: 33412753 ( click the link to review the publication )

J Mol Cell Biol, 2020, 11;12(5):359-371

PubMed: 31565729 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(5):4547-4557

PubMed: 32163373 ( click the link to review the publication )

Cytotherapy, 2020, S1465-3249(20)30929-4

PubMed: 33246884 ( click the link to review the publication )

Int J Oncol, 2020, 56(6):1429-1441

PubMed: 32236593 ( click the link to review the publication )

Genome Med, 2020, 12(1):63

PubMed: 32669118 ( click the link to review the publication )

Clin Transl Med, 2020, 10(6):e181

PubMed: 33135348 ( click the link to review the publication )

EBioMedicine, 2019, 43:201-210

PubMed: 30975544 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Mol Cell, 2018, 72(2):341-354

PubMed: 30270106 ( click the link to review the publication )

Nat Commun, 2018, 9(1):5378

PubMed: 30568163 ( click the link to review the publication )

Cancer Res, 2018, 78(2):572-583

PubMed: 29180474 ( click the link to review the publication )

J Immunol, 2018, 201(9):2744-2752

PubMed: 30249811 ( click the link to review the publication )
Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Front Pharmacol, 2018, 9:1166

PubMed: 30386240 ( click the link to review the publication )

Cell Tissue Res, 2018, 374(3):577-585

PubMed: 30182276 ( click the link to review the publication )

Nat Commun, 2017, 8:14802

PubMed: 28378740 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(14):8403-8410

PubMed: 28854735 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(9):1221-1229

PubMed: 28592703 ( click the link to review the publication )

Theranostics, 2016, 6(2):219-30

PubMed: 26877780 ( click the link to review the publication )

J Hematol Oncol, 2016, 9(1):134

PubMed: 27903272 ( click the link to review the publication )

Oncotarget, 2016, 7(3):2545-54

PubMed: 26575423 ( click the link to review the publication )

产品安全说明书

Epigenetic Reader Domain抑制剂选择性比较

生物活性

产品描述

I-BET151 (GSK1210151A)是一种新型，选择性的BET抑制剂，作用于BRD2，无细胞试验中BRD3和BRD4，IC50分别为0.5 μM， 0.25 μM和0.79 μM。

特性

优化I-BET151，使其有效及选择性靶向作用于BET，同时增强体内药代动力学和终末半衰期，以使延长体内研究。

靶点

BRD3 ^[1] (Cell-free assay)	BRD2 ^[1] (Cell-free assay)	BRD4 ^[1] (Cell-free assay)
0.25 μM	0.5 μM	0.79 μM

体外研究

I-BET151有效，选择性作用于多种不同蛋白类型，如COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, 离子通道，转运体。与I-BET762 (GSK525762A)类似, I-BET151 对BRD2, BRD3 和BRD4具有高的结合亲和力，K_d为0.02-0.1 μM,作用于人类外周血单核细胞（PBMC）和全血（WB）以及大鼠WB，显著抑制脂多糖刺激的IL-6细胞因子产生，IC50分别为0.16 μM, 1.26 μM, 和 1.26 μM。I-BET151(0.5 or 5 μM)作用于HL60核提取物，抑制BETs(BRD2, BRD3, BRD4, 和 BRD9)而非23种其他溴区蛋白结合到乙酰化的组蛋白肽。I-BET151有效作用于含不同 MLL融合的细胞系，如MV4;11, RS4;11, MOLM13, 和NOMO1 细胞， IC50为15-192 nM。一致的是，I-BET151完全消除MLL融合驱动的白血病（MOLM13）而非酪氨酸激酶激活（K562）驱动的白血病的菌落形成潜力。I-BET151也有效作用于液体培养和转化MLL-ENL或MLL-AF9的原代小鼠祖细胞的克隆形成实验。I-BET151作用于由不同的MLL融合（分别含MLL-AF9和MLL-AF4的MOLM13和MV4;11）而非K562细胞驱动的MLL融合细胞系，显著诱导细胞凋亡和G0/G1期停滞，可能是由于通过抑制BRD3/4，PAFc和SEC组分招募到转录起始位点（TSS），而抑制BCL-2，C-MYC和CDK6的转录。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MV4;11	NUnFNm9X[3m2b4TvfIlkcXS7IHHzd4F6	NULBeo1QhjFyMDFOwG0>		NYLWWm4zTE2VTx?=	NYfEfGpQUUN3ME2yOkBvVQ>?	NH3lN4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2OFM1OCd-MkG5OlQ{PDB:L3G+
RS4;11	M1rJOIN6fG:2b4jpZ4l1gSCjc4PhfS=>	MXP+NVAxKM7:TR?=		NETNSo9FVVOR	M2jk[mlEPTB;MUmyJI5O	NHfRRlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2OFM1OCd-MkG5OlQ{PDB:L3G+
MOLM13	MYLjfZRwfG:6aXPpeJkh[XO\|YYm=	MoHhglExOCEQvF2=		NXfobHhpTE2VTx?=	NILicIhKSzVyPUGyNEBvVQ>?	NWq3SJYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlQ{PDBpPkKxPVY1OzRyPD;hQi=>
NOMO1	NWnyfJZz[3m2b4TvfIlkcXS7IHHzd4F6	MnPOglExOCEQvF2=		NXrSRlM4TE2VTx?=	M17C[WlEPTB;MUWgcm0>	M3fWV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOU[0N\|QxLz5{MUm2OFM1ODxxYU6=
HEL	MnHTZ5l1d3SxeHnjbZR6KGG\|c3H5	Mn;YglExOCEQvF2=		MV\EUXNQ	M1XXcmlEPTB;MTFOwG0>	MmDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkSzOFAoRjJzOU[0N\|QxRC:jPh?=
K562	MlXyZ5l1d3SxeHnjbZR6KGG\|c3H5	NITORXZ,OTByIN88US=>		NVzXUXRVTE2VTx?=	M4TUeWlEPTB-MUCwJO69VQ>?	Mn\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NkSzOFAoRjJzOU[0N\|QxRC:jPh?=
MEG01	Mkf6Z5l1d3SxeHnjbZR6KGG\|c3H5	NYTFRohZhjFyMDFOwG0>		NWDWd2xkTE2VTx?=	NY\rUpRrUUN3ME2yOUDPxE1?	NEjRXYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2OFM1OCd-MkG5OlQ{PDB:L3G+
HL60	MVrjfZRwfG:6aXPpeJkh[XO\|YYm=	NIWweXd,OTByIN88US=>		MkHPSG1UVw>?	Ml;sTWM2OD16OUCgcm0>	NVfqbGQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlQ{PDBpPkKxPVY1OzRyPD;hQi=>
MV4;11	M{O3Z2Fxd3C2b4Ppd{Bie3OjeR?=	MnHTglExOCEQvF2=		MVvEUXNQ	NXjicFlmcW6mdXPld{BieG:ydH;zbZM>	NGDxUJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2OFM1OCd-MkG5OlQ{PDB:L3G+
MOLM13	M36wbmFxd3C2b4Ppd{Bie3OjeR?=	MkXaglExOCEQvF2=		MVLEUXNQ	MWDpcoR2[2W\|IHHwc5B1d3Orcx?=	NULpSGtRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OlQ{PDBpPkKxPVY1OzRyPD;hQi=>
MV4;11	M4nQNmZ2dmO2aX;uJIF{e2G7			M3XoT2ROW09?	NXjwRXZT\GWlcnXhd4V{KHSqZTDy[YNzfWm2bXXueEBw\iCEUlSzM\|Qh[W6mIHntdIFqemWmIILlZ5J2cXSvZX70JI9nKEOGS{mgZY5lKFCDRkGgeI8hfGinIITyZY5{[3KrcITpc45idCC\|dHHyeEB{cXSn	NH7iRpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm2OFM1OCd-MkG5OlQ{PDB:L3G+
PBMC	MkTCSpVv[3Srb36gZZN{[Xl?			NF;lWGRFVVOR	NWfGUoU5cW6qaXLpeJMhUUxvNjD3bZRpKHCLQ{WwJI9nKDZwNx?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR\|N{GxOUc,OjJ2M{exNVU9N2F-
A2	NVHtU29lTnWwY4Tpc44h[XO\|YYm=	NFTUV2N,OTBizszN		NHuyNI5FVVOR	NHjhVIJz\WGldHn2ZZRmeyCuYYTlcpQhUEmYLUG=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ3NUKxPEc,OjN{NUWyNVg9N2F-
A72	NITROZZHfW6ldHnvckBie3OjeR?=	M1Gycp4yOCEQvF2=		M2[0bGROW09?	NIe4PJVz\WGldHn2ZZRmeyCuYYTlcpQhUEmYLUG=	NXTJN5RkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOVUzOThpPkKzNlU2OjF6PD;hQi=>
BC1	MXnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnK3glEh\|ryP		M2LHPGROW09?	MWHJR\|UxRTJ{MDDuUS=>	NGfs[mE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlQ1QCd-MkO3PVI1PDh:L3G+
BC3	NHfvS41Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MoPaglEh\|ryP		NWPKcYszTE2VTx?=	M1KzWGlEPTB;NE[wJI5O	NH;zZYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlQ1QCd-MkO3PVI1PDh:L3G+
BCBL1	NEWz[JRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYLYTXY4hjFizszN		MnXJSG1UVw>?	NYOwWIczUUN3ME2zN\|Ahdk1?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkS0PEc,OjN5OUK0OFg9N2F-
BJAB	NEO5[G9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGTFS5l,OSEQvF2=		MYLEUXNQ	M1L5SmlEPTB;OUewJI5O	NULrUmd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PVI1PDhpPkKzO\|kzPDR6PD;hQi=>
Namalwa	MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MX;+NUDPxE1?		MV7EUXNQ	NUPTR3JnUUN3ME25O\|Ahdk1?	MknPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK0OFgoRjJ\|N{myOFQ5RC:jPh?=
Jurkat	NF\6O5JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXK1NFh4hjFizszN		M3S1UGROW09?	M3HuNGlEPTB;MUKyNEBvVQ>?	MnzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK0OFgoRjJ\|N{myOFQ5RC:jPh?=
MM1S	NWjQVlZ1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHzsSpB,OSEQvF2=		MoL4SG1UVw>?	Mn\MTWM2OD15NkCgcm0>	NGTyN2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{e5NlQ1QCd-MkO3PVI1PDh:L3G+
U266	MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MmPNglEh\|ryP		MXrEUXNQ	MlXuTWM2OD17NUCgcm0>	M2Sy[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{myOFQ5Lz5{M{e5NlQ1QDxxYU6=
UM-PEL-1	MY\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFvXbGl,OSEQvF2=		NUn6TZlRTE2VTx?=	NHLzRXZKSzVyPUKxNEBvVQ>?	MnzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK0OFgoRjJ\|N{myOFQ5RC:jPh?=
UM-PEL-3	NETYVG9Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NWLPR4RmhjFizszN		NILuS4JFVVOR	MXrJR\|UxRTF6MDDuUS=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkS0PEc,OjN5OUK0OFg9N2F-
BC1	NX36XZQxTnWwY4Tpc44h[XO\|YYm=	MX:1NFAhdk1?		M2XaXGROW09?	NXrhe5VJcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeC=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkS0PEc,OjN5OUK0OFg9N2F-
BC3	NYrpbplWTnWwY4Tpc44h[XO\|YYm=	MXu1NFAhdk1?		MnrhSG1UVw>?	MUTpcoR2[2W\|IHPlcIwu[3mlbHWgZZJz\XO2	MlPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN5OUK0OFgoRjJ\|N{myOFQ5RC:jPh?=
BC1	MUXGeY5kfGmxbjDhd5NigQ>?	MXi4NFAhdk1?		MVPEUXNQ	MWry[YR2[2W\|IHOtUZlkKHC{b4TlbY4hdGW4ZXzz	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MkS0PEc,OjN5OUK0OFg9N2F-
BC3	NIm4fXZHfW6ldHnvckBie3OjeR?=	NYriS\|JYQDByIH7N		NGTGdWtFVVOR	MknOdoVlfWOnczDjMW16[yCycn;0[YlvKGyndnXsdy=>	NYSwXHgxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3PVI1PDhpPkKzO\|kzPDR6PD;hQi=>
H929	NHTad25HfW6ldHnvckBie3OjeR?=	Mlr6glEh\|ryP		MnjVSG1UVw>?	NHTGO3lqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0	M1XBW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{O1OFk6Lz5{NEOzOVQ6QTxxYU6=
KMS12PE	M1X4eGZ2dmO2aX;uJIF{e2G7	NUfve3drhjFizszN		NWr6TolTTE2VTx?=	M1n2Nolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	NGO5S\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzOVQ6QSd-MkSzN\|U1QTl:L3G+
KMS12BM	MYLGeY5kfGmxbjDhd5NigQ>?	MojXglEh\|ryP		MVrEUXNQ	MXLpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2	NXXUPXRORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN\|U1QTlpPkK0N\|M2PDl7PD;hQi=>
KMS18	MXfGeY5kfGmxbjDhd5NigQ>?	NFfhNnZ,OSEQvF2=		MkXPSG1UVw>?	M2DFeYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	M1;kcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{O1OFk6Lz5{NEOzOVQ6QTxxYU6=
KMS11	NEOwU2RHfW6ldHnvckBie3OjeR?=	NVzVd4xIhjFizszN		NXPERlR1TE2VTx?=	M1S3eYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S=	NFTyd4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzOVQ6QSd-MkSzN\|U1QTl:L3G+
RPMI8226	NE\EPI9HfW6ldHnvckBie3OjeR?=	MYf+NUDPxE1?		MnvOSG1UVw>?	NXfFfoRGcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeC=>	NWrsZpBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN\|U1QTlpPkK0N\|M2PDl7PD;hQi=>
H929	MVfBdI9xfG:\|aYOgZZN{[Xl?	NWjXOpNVhjFizszN		MX;EUXNQ	NGXSPVZqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NG[4XIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEOzOVQ6QSd-MkSzN\|U1QTl:L3G+
KMS12PE	NXHUPGpUSXCxcITvd4l{KGG\|c3H5	MXX+NUDPxE1?		M33WTmROW09?	MnvKbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN\|NUS5PUc,OjR\|M{W0PVk9N2F-
KMS12BM	NVLKTFNqSXCxcITvd4l{KGG\|c3H5	NHPmZol,OSEQvF2=		MoD2SG1UVw>?	NXrtellzcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	Ml\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR\|M{W0PVkoRjJ2M{O1OFk6RC:jPh?=
KMS18	NGXkXIdCeG:ydH;zbZMh[XO\|YYm=	NXXkTZBxhjFizszN		NVi4N4RLTE2VTx?=	M2LJNIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN\|NUS5PUc,OjR\|M{W0PVk9N2F-
KMS11	NV7xZXlXSXCxcITvd4l{KGG\|c3H5	NFTkRZd,OSEQvF2=		NWfjO5dpTE2VTx?=	MnHlbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	M3zhblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{O1OFk6Lz5{NEOzOVQ6QTxxYU6=
RPMI8226	NIjxe4xCeG:ydH;zbZMh[XO\|YYm=	NVeyOVVQhjFizszN		M{\uWWROW09?	NYLrSVZbcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN\|NUS5PUc,OjR\|M{W0PVk9N2F-
U87MG	NWHZRWEyTnWwY4Tpc44h[XO\|YYm=	NWfDTItnhjFyIN88US=>		NF\CfnFFVVOR	NIfJT4Zz\WS3Y3XzJHU5P02JIHPlcIx2dGG{IFHUVEB4cXSqIFnDOVAhd2ZiMT6wOUDPxE1?	NWLRXIZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVY{QDFpPkK0OFk3OzhzPD;hQi=>
A172	M2nR[GZ2dmO2aX;uJIF{e2G7	MVr+NVAh\|ryP		NGD6OWJFVVOR	M1r3[ZJm\HWlZYOgZ4VtdHWuYYKgRXRRKHerdHigTWM2OCCxZjCxMlI5KM7:TR?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR7NkO4NUc,OjR2OU[zPFE9N2F-
SW1783	NV7XXolzTnWwY4Tpc44h[XO\|YYm=	NHLlclR,OTBizszN		NVjrclA{TE2VTx?=	M3q2dZJm\HWlZYOgZ4VtdHWuYYKgRXRRKHerdHigTWM2OCCxZjCyMlY5KM7:TR?=	NEjBW2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NES5OlM5OSd-MkS0PVY{QDF:L3G+
U87MG	MX3GeY5kfGmxbjDhd5NigQ>?	NYTRbXVthjFyIN88US=>		NIjxZWRFVVOR	MlPMbY5kemWjc3XzJJBzd3CxcoTpc44hd2ZiY3XscJMhcW5idHjlJGcyN1NidILhcpNqfGmxbh?=	NXXPdVQ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0PVY{QDFpPkK0OFk3OzhzPD;hQi=>
RAW267.4	M{K5RWZ2dmO2aX;uJIF{e2G7	M1m1UFEh\|ryP		MV7EUXNQ	MnXmdoVlfWOnczDJUE03KHC{b3T1Z5Rqd25iaX7keYNm\CCkeTDMVHM>	MmnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUmwNFgoRjJ2OEW5NFA5RC:jPh?=
RAW267.4	M{L1d2Z2dmO2aX;uJIF{e2G7	NW[yXWdSOSEQvF2=		NIPFWYpFVVOR	Mo[wdoVlfWOnczD0bIUh[XO\|b3PpZZRqd25iYnX0e4VmdiCEUlS0JIFv\CCjY3X0fYxifGWmIIC2OS=>	M3KwblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW5NFA5Lz5{NEi1PVAxQDxxYU6=
Me007	MnfHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NE\oXol,OTByIN88US=>		M4TYe2ROW09?	M3:5T4lvcGmkaYTzJJRp\SCpcn;3eIg>	MnPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7ME[xN\|coRjJ2OUC2NVM4RC:jPh?=
SK-Mel-28	NV\QZVZXT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MVn+NVAxKM7:TR?=		MWPEUXNQ	MXXpcohq[mm2czD0bIUh\3Kxd4To	NULVdVl1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFYyOzdpPkK0PVA3OTN5PD;hQi=>
Mel-RMU	NEfvVWRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUj+NVAxKM7:TR?=		NVzkblNqTE2VTx?=	MUjpcohq[mm2czD0bIUh\3Kxd4To	NEC3e4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOlE{Pyd-MkS5NFYyOzd:L3G+
Mel-JD	NFPERYVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NX;BPXJjhjFyMDFOwG0>		NEWxTpBFVVOR	NGXvUIpqdmirYnn0d{B1cGViZ4Lve5Rp	M4HPXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUC2NVM4Lz5{NEmwOlE{PzxxYU6=
Mel-RM	Ml3FS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIfyfnJ,OTByIN88US=>		M{nhc2ROW09?	MYXpcohq[mm2czD0bIUh\3Kxd4To	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNkGzO{c,OjR7ME[xN\|c9N2F-
Me007	M1jwUWFxd3C2b4Ppd{Bie3OjeR?=	NE\QdGx,OTByIN88US=>		M1j3d2ROW09?	NXTwR\|dscW6mdXPld{BieG:ydH;zbZM>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNkGzO{c,OjR7ME[xN\|c9N2F-
SK-Mel-28	MmXLRZBweHSxc3nzJIF{e2G7	NGnEdmh,OTByIN88US=>		NGG3WFBFVVOR	NXOxdIY2cW6mdXPld{BieG:ydH;zbZM>	NVTXdINDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFYyOzdpPkK0PVA3OTN5PD;hQi=>
Mel-RMU	M3XWPWFxd3C2b4Ppd{Bie3OjeR?=	NGrUXWF,OTByIN88US=>		NV\LNXZGTE2VTx?=	Mmq5bY5lfWOnczDhdI9xfG:\|aYO=	MnjCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7ME[xN\|coRjJ2OUC2NVM4RC:jPh?=
Mel-JD	NVW2fIFLSXCxcITvd4l{KGG\|c3H5	NWLBUJBJhjFyMDFOwG0>		NFLlOnFFVVOR	MV;pcoR2[2W\|IHHwc5B1d3Orcx?=	NVK4bolDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFYyOzdpPkK0PVA3OTN5PD;hQi=>
Mel-RM	NV7JVo1LSXCxcITvd4l{KGG\|c3H5	MXj+NVAxKM7:TR?=		NF7ifFFFVVOR	MVfpcoR2[2W\|IHHwc5B1d3Orcx?=	MnnTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7ME[xN\|coRjJ2OUC2NVM4RC:jPh?=
Me007	M{L3UWZ2dmO2aX;uJIF{e2G7	MnvKNVAh\|ryP		M1\ZbmROW09?	MUnpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE>	NILC[mo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOlE{Pyd-MkS5NFYyOzd:L3G+
SK-Mel-28	NIO0PWhHfW6ldHnvckBie3OjeR?=	NELteFEyOCEQvF2=		NHW1bnhFVVOR	MmHDbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy	NVLxTodmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFYyOzdpPkK0PVA3OTN5PD;hQi=>
Mel-RMU	MYDGeY5kfGmxbjDhd5NigQ>?	NHPuSVgyOCEQvF2=		MkjRSG1UVw>?	NW\iZmlHcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeEBjgSC3cILl[5Vt[XSrb36gc4YheDJz	M2fpblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUC2NVM4Lz5{NEmwOlE{PzxxYU6=
Mel-JD	MkPUSpVv[3Srb36gZZN{[Xl?	NGD0bocyOCEQvF2=		MUnEUXNQ	MX\pcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHL5JJVxemWpdXzheIlwdiCxZjDwNlE>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNkGzO{c,OjR7ME[xN\|c9N2F-
Mel-RM	NIjZR49HfW6ldHnvckBie3OjeR?=	Mk\LNVAh\|ryP		M4LWR2ROW09?	Mm\jbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDifUB2eHKnZ4XsZZRqd25ib3[gdFIy	NWLEOI5CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFYyOzdpPkK0PVA3OTN5PD;hQi=>
Me007	M4XlSWZ2dmO2aX;uJIF{e2G7	NILuVY8yOCEQvF2=		MoP4SG1UVw>?	MYf1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW\|	NHrlc5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwOlE{Pyd-MkS5NFYyOzd:L3G+
SK-Mel-28	NFz6eYZHfW6ldHnvckBie3OjeR?=	M{TJeFExKM7:TR?=		MWDEUXNQ	NIHGU2Z2eHKnZ4XsZZRmeyCycn;hdI9xfG:2aXOgZY5lKGOnbHygZ5lkdGViYYLy[ZN1KGenbnXz	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNkGzO{c,OjR7ME[xN\|c9N2F-
Mel-RMU	NYXPVm1sTnWwY4Tpc44h[XO\|YYm=	NGe4NHkyOCEQvF2=		MUnEUXNQ	M2jkWJVxemWpdXzheIV{KHC{b3Hwc5B1d3SrYzDhcoQh[2WubDDjfYNt\SCjcoLld5Qh\2WwZYO=	MoLNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7ME[xN\|coRjJ2OUC2NVM4RC:jPh?=
Mel-JD	NGXvPZJHfW6ldHnvckBie3OjeR?=	NXf5SHhQOTBizszN		MYDEUXNQ	MUD1dJJm\3WuYYTld{Bxem:jcH;weI91cWNiYX7kJINmdGxiY4njcIUh[XK{ZYP0JIdmdmW\|	NVXDT\|J[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFYyOzdpPkK0PVA3OTN5PD;hQi=>
Mel-RM	MXrGeY5kfGmxbjDhd5NigQ>?	M3G0TVExKM7:TR?=		MUnEUXNQ	NUDU[5l{fXC{ZXf1cIF1\XNicILvZZBweHSxdHnjJIFv\CClZXzsJIN6[2ynIHHydoV{fCCpZX7ldy=>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDlyNkGzO{c,OjR7ME[xN\|c9N2F-
HepG2	MkXhSpVv[3Srb36gZZN{[Xl?		MYixPEBpenN?		M3q2fXVxemWpdXzheIlwdiCxZjDBdI9COSCneIDy[ZN{cW:wIHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W\|c3XkJIF{KGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6lcnXhd4UhPzBnIH;mJIx2[2moZYLhd4Uh[WO2aY\peJkh[W[2ZYKgNVghcHK\|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVOxO\|AhRSByLkC5JO69VS5?	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjN6NkWyPUc,OjJ\|OE[1Nlk9N2F-
Raji	NFu1dWFHfW6ldHnvckBie3OjeR?=		MV60JIhzew>?		NEPNcm9KdmirYnn0bY9vKG:oIFLSSFQhcW5iaIXtZY4hWmGsaTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhVVmFIHX4dJJme3Orb36gZYZ1\XJiNDDodpMtKEmFNUCgQUAxNjF\|IN88UU4>	NXzkW2ExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA4PThpPkK0PVAxPzV6PD;hQi=>
MV4-11	M{\4SWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2XUWFczKGi{cx?=		NWfjbJdyT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVVZ2LUGxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkGxPUDPxE1w	M2G0PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW5OFI5Lz5{NUW1PVQzQDxxYU6=
MM1S	MnrvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXHtfmdKPzJiaILz		M330ZWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1OOVNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFAvOjl7IN88UU4>	NGLnNFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW1PVQzQCd-MkW1OVk1Ojh:L3G+
HT-29	M1rwdWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mn\QO\|IhcHK\|		MUHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE46PDVizszNMi=>	M1fO[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUW5OFI5Lz5{NUW1PVQzQDxxYU6=
Rosetta2 DE3	Mnf2SpVv[3Srb36gZZN{[Xl?		MWSzNEBucW6\|		MoflSIl{eGyjY3Xt[Y51KG:oIF\BUU1t[WKnbHXkJHpDSTJ2ODDmdo9uKEKURESgRmQyKCh2NDD0c{AyPjhiYX3pco8h[WOrZDDy[ZNq\HWnczmgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hWm:\|ZYT0ZVIhTEV\|IHPlcIx{KGGodHXyJFMxKG2rboOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygTWM2OCB;IECuNFMyPyEQvF2u	MnPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
MV4-11	NGrNTpNEgXSxdH;4bYNqfHliYYPzZZk>		MYS0JIRigXN?		MmruR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGijcnLvdolv\yCPTFyxJIZ2e2mxbjDn[Y5mKGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDRiZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGG\|c3H5MEBKSzVyIE2gNE4yPjJizszNMi=>	M1\DVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	MVjGeY5kfGmxbjDhd5NigQ>?		NWrUTZhWOzBibXnudy=>		NUTyRlVXTGm\|cHzhZ4Vu\W62IH;mJGZCVS2uYXLlcIVlKFqEQUK0PEBnem:vIFLSSFQhSkR{IDizN\|MhfG9iNE[wJIFucW6xIHHjbYQhemW\|aXT1[ZMqKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGLvd4V1fGF{IFTFN{Bk\WyuczDh[pRmeiB\|MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iYYPzZZktKEmFNUCgQUAxNjJ{NjFOwG0v	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
MOLM13	NHLhblZEgXSxdH;4bYNqfHliYYPzZZk>		NY\xUWhRPCCmYYnz		M4P4e2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1QVE1zMzDj[YxteyCqYYLic5JqdmdiTVzMNUBnfXOrb36g[4Vv\SCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2IHThfZMh[nliQ3XscHRqfGW{LVfsc{BtfW2rbnXzZ4VvfCCjc4PhfUwhUUN3MDC9JFAvOjJ6IN88UU4>	NYfLXmRlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NIO0V5JHfW6ldHnvckBie3OjeR?=		MYGzNEBucW6\|		Ml75TY5pcWKrdHnvckBw\iCIQV2tcIFj\WynZDDaRmEzPDhiYnnu[Ilv\yC2bzDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGhqezZvdHHn[4VlKEKURESgZpJwdW:mb33hbY4hOSBqNESgeI8hOTZ6IILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4hWm:\|ZYT0ZVIhTEV\|IHPlcIx{KGGodHXyJFMxKG2rboOgZpkhTmyxdYLld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygTWM2OCB;IECuNFMyPyEQvF2u	M{nvUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[zOFg4Lz5{OES2N\|Q5PzxxYU6=
MV4-11	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NXraXldZPCCmYYnz		M2ixOWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1XPC1zMTDj[YxteyCjZoTldkA1KGSjeYOgZpkhX1OWLUigZZN{[XluIFnDOVAhRSByLkG2NkDPxE1w	M1PsWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[zOFg4Lz5{OES2N\|Q5PzxxYU6=
Rosetta2 DE3	M131NGZ2dmO2aX;uJIF{e2G7		MUCzNEBucW6\|		MYDJcohq[mm2aX;uJI9nKE[DTT3sZYJmdGWmIGrCRVI1QCCkaX7kbY5oKHSxIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhSlKGNDDido9ud2SxbXHpckAzKCh\|M{OgeI8hPDZyIILld4llfWW\|KTDlfJBz\XO\|ZXSgbY4hWm:\|ZYT0ZVIhTEV\|IHPlcIx{KGGodHXyJFMxKG2rboOgZpkhTmyxdYLld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygTWM2OCB;IECuNlI3KM7:TT6=	NEPpWIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES2N\|Q5Pyd-Mki0OlM1QDd:L3G+
MOLM13	NHrVWFFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2XCZVQh\GG7cx?=		M{D6Xmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1QVE1zMzDj[YxteyCjZoTldkA1KGSjeYOgZpkhX1OWLUigZZN{[XluIFnDOVAhRSByLkKyPEDPxE1w	NV\tVYx5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OlM1QDdpPkK4OFY{PDh5PD;hQi=>
Rosetta2 DE3	M3rOZWZ2dmO2aX;uJIF{e2G7				NX6yNIQ4SmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFOyCEREGgLFI1KHSxIEG0OEBidWmwbzDhZ4llKHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDSc5NmfHSjMjDESVMh[2WubIOgZpkh[mmxLXzhfYVzKGmwdHXy[oVzd22ndIL5JI1mfGixZDygT4QhRSByLkCyPVgh\|ryPLh?=	MoraQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	NX\Td3lSTnWwY4Tpc44h[XO\|YYm=				NUfyNYc5SmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFOyCEREKgLFMxPiC2bzC0NVch[W2rbn:gZYNq\CC{ZYPp[JVmeyliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gVo9{\XS2YUKgSGU{KGOnbHzzJIJ6KGKrbz3sZZlmeiCrboTldoZmem:vZYTyfUBu\XSqb3SsJGtlKD1iMD6wOFA2KM7:TT6=	NVXTTpBTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NUnYfXVtTnWwY4Tpc44h[XO\|YYm=				NWCyUYduSmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFPCCEREGgLFQ1KHSxIEG2PEBidWmwbzDhZ4llKHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDSc5NmfHSjMjDESVMh[2WubIOgZpkh[mmxLXzhfYVzKGmwdHXy[oVzd22ndIL5JI1mfGixZDygT4QhRSByLkC1Nlgh\|ryPLh?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	NGT6[FhHfW6ldHnvckBie3OjeR?=				NHTFXHZDcW6maX7nJIFn\mmwaYT5JJRwKGKrb4Tpcplt[XSnZDDCVmQzKEKGMTCoO\|IhfG9iMkC1JIFucW6xIHHjbYQhemW\|aXT1[ZMqKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGLvd4V1fGF{IFTFN{Bk\WyuczDifUBjcW9vbHH5[ZIhcW62ZYLm[ZJwdWW2comgcYV1cG:mLDDL[EA:KDBwMEW0PEDPxE1w	NVHhPIpPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NV\mUmJQTnWwY4Tpc44h[XO\|YYm=				Mlz6Rolv\GmwZzDh[oZqdmm2eTD0c{BjcW:2aX75cIF1\WRiQmLENkBDTDJiKEO0PUB1dyB2NkCgZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy\|IHL5JIJqdy2uYYnldkBqdnSncn\ldo9u\XS{eTDt[ZRpd2RuIFvkJF0hOC5yN{CzJO69VS5?	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	NXrPWIkzTnWwY4Tpc44h[XO\|YYm=				NIDGTnhDcW6maX7nJIFn\mmwaYT5JJRwKGKrb4Tpcplt[XSnZDDCVmQ1KEKGMjCoN\|M{KHSxIES2NEBidWmwbzDhZ4llKHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDSc5NmfHSjMjDESVMh[2WubIOgZpkh[mmxLXzhfYVzKGmwdHXy[oVzd22ndIL5JI1mfGixZDygT4QhRSByLkKxOUDPxE1w	Mo\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3	MX3GeY5kfGmxbjDhd5NigQ>?				MXXCbY5lcW6pIHHm[olvcXS7IITvJIJqd3SrbonsZZRm\CCFUlXCRnAhMDFyNEOgeI8hOTF3OTDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYomgZolwNWyjeXXyJIlvfGW{ZnXyc41mfHK7IH3leIhw\CxiS3SgQUA{NjB6NDFOwG0v	M1n4RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	M1vjSWZ2dmO2aX;uJIF{e2G7		MlvGN\|AhdWmwcx?=		MljpSIl{eGyjY3Xt[Y51KG:oIF\BUU1t[WKnbHXkJHpDSTJ2ODDmdo9uKEKUREOgRmQyKCh{NDD0c{AyPDRiYX3pco8h[WOrZDDy[ZNq\HWnczmgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hWm:\|ZYT0ZVIhTEV\|IHPlcIx{KGGodHXyJFMxKG2rboOgZpkh\my3b4Lld4NmdmOnIIDvcIFzcXqjdHnvckBie3OjeTygT4khRSByLkCwO\|Ih\|ryPLh?=	M4rs[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3	NGPOUFFHfW6ldHnvckBie3OjeR?=		Mn7WN\|AhdWmwcx?=		M1;4cGRqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlS0JGJFOSBqNESgeI8hOTZ6IHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO\|YYmsJGtqKD1iMD6wNFkh\|ryPLh?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3	MV;GeY5kfGmxbjDhd5NigQ>?		NXH6c2FGOzBibXnudy=>		NEn3b49FcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLENkBDTDFiKEeyJJRwKDJyNTDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBMcSB;IECuNFA6KM7:TT6=	NYixdoFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	NX7Tc4QxTnWwY4Tpc44h[XO\|YYm=		NUnkbWRVOzBibXnudy=>		NEH3bG5FcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLEN{BDTDJiKEOwOkB1dyB2MUegZY1qdm9iYXPp[EBz\XOrZIXld{khMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iUn;z[ZR1[TJiRFWzJINmdGy\|IHHmeIVzKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJJBwdGG{aYrheIlwdiCjc4PhfUwhU2liPTCwMlAzOjNizszNMi=>	NWDIT\|lvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3	MVLGeY5kfGmxbjDhd5NigQ>?		NY\0XGc6OzBibXnudy=>		M335OGRqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlSyJGJFOiBqM{S5JJRwKDR4MDDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBMcSB;IECuNFQ6PiEQvF2u	NHW5flU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	M3P5XGZ2dmO2aX;uJIF{e2G7		NI\YT2k{OCCvaX7z		M{DGcGRqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlS0JGJFOiBqM{OzJJRwKDR4MDDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBMcSB;IECuNFc1QCEQvF2u	NGe5UW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3	NHnwdXBHfW6ldHnvckBie3OjeR?=		MWCzNEBucW6\|		MUfJcohq[mm2aX;uJI9nKE[DTT3sZYJmdGWmIGrCRVI1QCCkaX7kbY5oKHSxIILlZ49u[mmwYX70JIh2dWGwIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhSlKGNDDido9ud2SxbXHpckAyKCh2NDD0c{AyPjhicnXzbYR2\XNrIHX4dJJme3OnZDDpckBTd3OndIThNkBFTTNiY3XscJMh[W[2ZYKgN\|AhdWmwczDifUBHdG:3cnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDLbUA:KDBwMEC5JO69VS5?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
Rosetta2 DE3	M3nUO2Z2dmO2aX;uJIF{e2G7		NHjpfGg{OCCvaX7z		M1mzPGlvcGmkaYTpc44hd2ZiRlHNMYxi[mWuZXSgXmJCOjR6IHLpcoRqdmdidH:gdoVkd22kaX7hcpQhcHWvYX6gUk11\XKvaX7hcEBJcXN4LYTh[4dm\CCEUlS0JIJzd22xZH;tZYlvKDJiKEOzN{B1dyB2NkCgdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCIbH;1doV{[2WwY3WgdI9t[XKrenH0bY9vKGG\|c3H5MEBMcSB;IECuNFc1QCEQvF2u	MljUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
THP1	M3jlW2FvfGmrbn\sZY1u[XSxcomgZZN{[Xl?				MmnORY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBpfW2jbjDUTHAyKGOnbHzz	NVHBXI0xRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzPFY2OjlpPkKyN\|g3PTJ7PD;hQi=>
HT-29	MorXSpVv[3Srb36gZZN{[Xl?	MnzHNE4{OTJ3IIXNJJRwKDVidV2=	MV2yOEBpenN?		MlLmTY5pcWKrdHnvckBw\iCEUlS0JIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBkNU27YzDwdo91\WmwIHX4dJJme3Orb36gZZQhOC5\|MUK1JJVOKHSxIEWgeW0hfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcochdWW2aH;k	NV[xNlNIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1OVk1OjhpPkK1OVU6PDJ6PD;hQi=>
MV4-11	NELhbJlHfW6ldHnvckBie3OjeR?=				MoXGTY5pcWKrdHnvckBw\iCEUlS0JIlvKGi3bXHuJG1XPC1zMTDj[YxteyCjc4Pld5Nm\CCjczDkc5dvemWpdXzheIlwdiCxZjDCR2wzKFKQQTDlfJBz\XO\|aX;uJIJ6KFKQQT3z[ZEh[W6jbInzbZM>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ3OUe1NUc,Ojl{NUm3OVE9N2F-
MV4-11	Ml21SpVv[3Srb36gZZN{[Xl?				NUjTT5BJUW6qaXLpeIlwdiCxZjDCVmQ1KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBkVVmFIGLORUBmgHC{ZYPzbY9vKGK7IGLORU1{\XFiYX7hcJl{cXN?	NGOzfXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUK1PVc2OSd-MkmyOVk4PTF:L3G+
U-2 OS	NF7tPFVyUFSVIHHzd4F6				MnW3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	NHzFdm9yUFSVIHHzd4F6				NIfJeVZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	NXXiVI5TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	NUTYcIVweUiWUzDhd5NigQ>?				NYfMVFZqeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFTBU3kh[2WubIO=	NV74SmJJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NGrCe3VyUFSVIHHzd4F6				M2S4XJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	NFfBb2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
RD	MVnxTHRUKGG\|c3H5				NEG3WFFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	MlTxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NYK0S4REeUiWUzDhd5NigQ>?				MoD0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	NYGzNG8zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	NU\4NJNQeUiWUzDhd5NigQ>?				MkHhdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	M3;QPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NG\zU5VyUFSVIHHzd4F6				Mn3ldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	MVrxTHRUKGG\|c3H5				MnjidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NY\6[WhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	M{e2O5FJXFNiYYPzZZk>				MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	M4HCPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
fibroblast cells	M2HiXZFJXFNiYYPzZZk>				NIO5XGZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiY3;ueJJwdCCKaDD3bYxlKHS7cHWg[oljem:kbHHzeEBk\Wyucx?=	M3fFXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NIHufHJyUFSVIHHzd4F6				MWTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NH74NJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	MXzxTHRUKGG\|c3H5				NXTF[VAzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoN\|Ah[2WubIO=	NXrjWFdiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	MmTBdWhVWyCjc4PhfS=>				NFLLfm5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NVrkVmxORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	M2[z[pFJXFNiYYPzZZk>				M3vHV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	NE[z[po9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	MYjxTHRUKGG\|c3H5				MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NHTiUWhyUFSVIHHzd4F6				M3jUU5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	Ml33dWhVWyCjc4PhfS=>				NUTz[pBteUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	Mnn3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-SMA / Fibronectin / Collagen-1; PubMed: 27732564 Oncotarget Normally cultured NRK-49F cells were treated with I-BET151 (0-5μM) for 36 h. Then, cell lysates were prepared and subjected to immunoblot analysis with antibodies against α-SMA, collagen-1, fibronectin, and GAPDH. FoxM1 / AURKB / Survivin / cyclin B / PLK1; PubMed: 26877780 Theranostics OVTOKO and OVCA420 cells were treated with DMSO, JQ1 (1 μM) or I-BET151 (1 μM). Cell lysates were immunoblotted with indicated antibodies. HP1α / HP1β / HP1γ; PubMed: 30386240 Front Pharmacol Protein expression levels of HP1α, β, and γ in U937, R-U937, HL-60, and R-HL-60 cells after incubation with I-BET151 at indicated dose for 48 h. Typical blots from a representative experiment are shown. The experiments were repeated three times.	27732564 26877780 30386240

体内研究

I-BET151每天按30 mg/kg剂量处理小鼠，显著抑制鼠类MLL-AF9和人类MLL-AF4白血病肿瘤生长，显著延长寿命。^[1]

激酶实验： ^[1]	- 合并荧光各向异性（FP）的配体位移检测: 所有组分溶解在50 mM HEPES pH 7.4, 150 mM NaCl和 0.5 mM CHAPS组成的Buffer中，BRD 2/3/4终浓度为75 nM，荧光配体为5 nM。在Greiner 384孔黑色的低量微孔板中，使用Micro Multidrop 将10 μL反应混合物加入到含100 nL各种浓度I-BET151或DMSO空白对照（1%最终）的孔中，并在黑暗中室温下平衡60分钟。使用 Envision (lex=485 nm，lEM=530 nm；Dichroic=505 nM)读取荧光各向异性。
细胞实验： ^[1]	- 合并 Cell lines: MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 和 K562 Concentrations: 溶于DMSO, 终浓度为~100 μM Incubation Time: 24,或72小时 Method: 使用多种不同浓度I-BET151在384孔或96孔板中处理细胞24或72小时。细胞生长抑制实验中，实验板每孔中加入与细胞培养基同等体积的CellTiter-Glo试剂，震荡约2分钟，然后在Analyst GT 或EnVision酶标仪上读取化学发光信号。细胞增殖实验中，每孔加入CellTiter-Aqueous One，然后实验板在37°C下温育4小时。在SpectraMax Gemini酶标仪上490 nm处读取吸光度。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 静脉注射MV4;11细胞的NOD-SCID小鼠,静脉注射MLL-AF9细胞的C57BL/6小鼠 Dosages: ~30 mg/kg/day Administration: 腹腔注射 (Only for Reference)

参考文献

[1] Dawson MA, et al. Nature, 2011, 478(7370), 529-533.

溶解度 (25°C)

体外	Ethanol	27 mg/mL (64.99 mM)
	DMSO	Insoluble
	Water	Insoluble

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download I-BET151 (GSK1210151A) SDF

分子量	415.44
化学式	C₂₃H₂₁N₅O₃
CAS号	1300031-49-5
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

选择性强的BET抑制剂

PFI-1 (PF-6405761) : BRD4-selective, IC50=0.22 μM.
活性最高的BET抑制剂

I-BET-762 : BET proteins, IC50=~35 nM.
用于临床的BET抑制剂

RVX-208 ^New : Phase II for Dyslipidemia.
最新的BET抑制剂

Bromosporine : Broad spectrum inhibitor for bromodomains with IC50 of 0.41 μM, 0.29 μM, 0.122 μM and 0.017 μM for BRD2, BRD4, BRD9 and CECR2, respectively.

研究领域

产品类型

定制您的化合物库

I-BET151 (GSK1210151A)

客户使用Selleck生产的I-BET151 (GSK1210151A)发表文献33篇：

产品安全说明书

Epigenetic Reader Domain抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download I-BET151 (GSK1210151A) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features